Marktanalyse - Primary Biliary Cirrhosis - Pipeline Review, H1 2017

Global Markets Direct
02.2017
95 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Primary Biliary Cirrhosis - Pipeline Review, H1 2017


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cirrhosis — Pipeline Review, H1 2017, provides an overview of the Primary Biliary Cirrhosis (Gastrointestinal) pipeline landscape.

Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cirrhosis — Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Phase 0 stages are 1, 1, 9, 5 and 1 respectively.

Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Biliary Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Biliary Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Primary Biliary Cirrhosis - Overview

Primary Biliary Cirrhosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Primary Biliary Cirrhosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Primary Biliary Cirrhosis - Companies Involved in Therapeutics Development

Albireo Pharma Inc

Arena Pharmaceuticals Inc

CymaBay Therapeutics Inc

Eisai Co Ltd

Enanta Pharmaceuticals Inc

Genextra Spa

Genfit SA

GenKyoTex SA

Gilead Sciences Inc

GlaxoSmithKline Plc

MediGene AG

NGM Biopharmaceuticals Inc

Novartis AG

Retrophin Inc

Shire Plc

Virobay Inc

Primary Biliary Cirrhosis - Drug Profiles

A-4250 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-6011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EDP-305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elafibranor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etrasimod arginine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FFP-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GKT-831 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-9674 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2330672 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJN-452 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

maralixibat chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGM-282 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

obeticholic acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RhuDex - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seladelpar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ursodiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-825 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Primary Biliary Cirrhosis - Dormant Projects

Primary Biliary Cirrhosis - Product Development Milestones

Featured News & Press Releases

Nov 04, 2016: GENFIT: FDA has officially cleared the IND to proceed with Phase II trial and evaluate elafibranor in PBC

Oct 20, 2016: CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of a Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With Primary Biliary Cholangitis at the AASLD 2016 Liver Meeting

Oct 20, 2016: CymaBay Therapeutics Announces that MBX-8025 has Received European Medicines Agency PRIority MEdicines Designation for the Treatment of Primary Biliary Cholangitis

Oct 05, 2016: CymaBay Therapeutics Announces Plans to Initiate Its Next Phase 2 Study of MBX-8025 in Primary Biliary Cholangitis

Aug 17, 2016: New England Journal of Medicine Publishes Results of Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC

May 31, 2016: CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC)

May 27, 2016: FDA Grants Accelerated Approval to Ocaliva (Obeticholic Acid) for the Treatment of Patients with PBC

May 18, 2016: Intercept Announces Ocaliva (Obeticholic Acid) Data in PBC to be Presented at DDW 2016

Apr 14, 2016: New Analyses of the Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC Presented at EASL

Apr 07, 2016: FDA Advisory Committee Unanimously Recommends Accelerated Approval of Ocaliva (obeticholic acid) for the Treatment of PBC

Mar 30, 2016: Intercept Announces New OCA Data in PBC and NASH to be Presented at EASL 2016

Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohn’s Disease with anti-CD40 Monoclonal Antibody

Dec 17, 2015: FDA Extends PDUFA Date for Obeticholic Acid for the Treatment of PBC

Nov 14, 2015: Intercept Presents New PBC Data at AASLD 2015

Nov 10, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer





List of Tables

Number of Products under Development for Primary Biliary Cirrhosis, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Primary Biliary Cirrhosis - Pipeline by Albireo Pharma Inc, H1 2017

Primary Biliary Cirrhosis - Pipeline by Arena Pharmaceuticals Inc, H1 2017

Primary Biliary Cirrhosis - Pipeline by CymaBay Therapeutics Inc, H1 2017

Primary Biliary Cirrhosis - Pipeline by Eisai Co Ltd, H1 2017

Primary Biliary Cirrhosis - Pipeline by Enanta Pharmaceuticals Inc, H1 2017

Primary Biliary Cirrhosis - Pipeline by Genextra Spa, H1 2017

Primary Biliary Cirrhosis - Pipeline by Genfit SA, H1 2017

Primary Biliary Cirrhosis - Pipeline by GenKyoTex SA, H1 2017

Primary Biliary Cirrhosis - Pipeline by Gilead Sciences Inc, H1 2017

Primary Biliary Cirrhosis - Pipeline by GlaxoSmithKline Plc, H1 2017

Primary Biliary Cirrhosis - Pipeline by MediGene AG, H1 2017

Primary Biliary Cirrhosis - Pipeline by NGM Biopharmaceuticals Inc, H1 2017

Primary Biliary Cirrhosis - Pipeline by Novartis AG, H1 2017

Primary Biliary Cirrhosis - Pipeline by Retrophin Inc, H1 2017

Primary Biliary Cirrhosis - Pipeline by Shire Plc, H1 2017

Primary Biliary Cirrhosis - Pipeline by Virobay Inc, H1 2017

Primary Biliary Cirrhosis - Dormant Projects, H1 2017





List of Figures

Number of Products under Development for Primary Biliary Cirrhosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus